Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by CENTRAL TRUST Co

CENTRAL TRUST Co reduced its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 18.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,697 shares of the specialty pharmaceutical company’s stock after selling 389 shares during the quarter. CENTRAL TRUST Co’s holdings in Jazz Pharmaceuticals were worth $209,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in the business. GAMMA Investing LLC raised its holdings in Jazz Pharmaceuticals by 41.3% during the third quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock worth $46,000 after purchasing an additional 121 shares during the last quarter. UMB Bank n.a. raised its holdings in Jazz Pharmaceuticals by 70.9% during the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after purchasing an additional 129 shares during the last quarter. Ellsworth Advisors LLC raised its holdings in Jazz Pharmaceuticals by 0.4% during the fourth quarter. Ellsworth Advisors LLC now owns 37,962 shares of the specialty pharmaceutical company’s stock worth $4,675,000 after purchasing an additional 149 shares during the last quarter. Exchange Traded Concepts LLC raised its holdings in Jazz Pharmaceuticals by 2.2% during the fourth quarter. Exchange Traded Concepts LLC now owns 7,045 shares of the specialty pharmaceutical company’s stock worth $868,000 after purchasing an additional 155 shares during the last quarter. Finally, Cooper Financial Group raised its holdings in Jazz Pharmaceuticals by 3.7% during the fourth quarter. Cooper Financial Group now owns 4,334 shares of the specialty pharmaceutical company’s stock worth $534,000 after purchasing an additional 156 shares during the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

JAZZ has been the subject of several recent research reports. Needham & Company LLC reissued a “buy” rating and set a $207.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Morgan Stanley raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $140.00 to $175.00 in a research report on Thursday, December 12th. TD Cowen dropped their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Robert W. Baird raised their price target on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research report on Monday, November 18th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $179.00 price target on shares of Jazz Pharmaceuticals in a research report on Tuesday, December 10th. Two equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $177.00.

Insider Activity at Jazz Pharmaceuticals

In other news, EVP Neena M. Patil sold 3,700 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the transaction, the executive vice president now directly owns 33,048 shares of the company’s stock, valued at approximately $4,078,453.68. This represents a 10.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Bruce C. Cozadd sold 1,500 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total value of $185,145.00. Following the transaction, the chief executive officer now directly owns 425,525 shares of the company’s stock, valued at $52,522,550.75. This trade represents a 0.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 7,253 shares of company stock valued at $890,594 over the last three months. 4.20% of the stock is owned by insiders.

Jazz Pharmaceuticals Stock Down 0.3 %

Shares of Jazz Pharmaceuticals stock opened at $121.63 on Wednesday. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The firm has a market cap of $7.35 billion, a P/E ratio of 17.13, a P/E/G ratio of 0.90 and a beta of 0.56. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $134.17. The business has a 50-day moving average price of $122.62 and a 200 day moving average price of $116.28.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.